The Latest Regenerative Medicine Articles from Streetwise Reports


Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

  ()
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.
Tags:  Regenerative MedicineBiotechnology / Pharmaceuticals

Showing Results: 1 to 1 of 1

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts